Galapagos NV is bolstering its ability to select drug targets and compounds by acquiring Inpharmatica Ltd in an all-share transaction that values the UK bioinformatics company at €12.5 million.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.